The previously mentioned studies illustrate the effectiveness of IL‐24 in combination with chemotherapeutic drugs, small molecule inhibitors, radiation therapy, and other approaches (Figure 4) in modulating key pathways and restraining tumor growth across diverse preclinical cancer models. The gene discussed is IL24; the disease is neoplasm.